Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results, Beats Estimates By $0.06 EPS

Autolus Therapeutics (NASDAQ:AUTL) released its earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06, FiscalAI reports. The firm had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL net product revenue rose to $45.7 million in Q2 2026, up from $26.2 million in Q1 and $20.9 million a year earlier. Management raised full-year 2026 revenue guidance to $140 million–$150 million.
• Commercial expansion is progressing faster than planned, with more than 80 U.S. authorized treatment centers already active by midyear and approximately 20 U.K. centers expected by year-end. Management said most activated centers have already treated patients and reported strong physician adoption.
• Gross margin improved sharply to 55% from 6% in Q1, driven by higher manufacturing volumes, production at the U.K. Nucleus facility, operating efficiencies, and cost reductions. The company is targeting a 65%–70% gross margin for the mature adult ALL business within roughly 12–18 months.
• Management outlined multiple upcoming clinical catalysts, including longer-term CARLYSLE lupus data and initial AUTO8 amyloidosis data by year-end 2026, BOBCAT progressive multiple sclerosis data in 2027, and potential pediatric ALL and lupus nephritis milestones in 2027–2028.
• Autolus drew an initial $75 million under a Perceptive Advisors credit facility, with up to $250 million potentially available subject to revenue milestones. Combined with cash, marketable securities, and anticipated revenue, management expects runway into Q2 2028, though the financing increases future debt obligations.

Autolus Therapeutics Stock Performance

Shares of AUTL stock traded up $0.17 during trading hours on Tuesday, hitting $2.23. The company had a trading volume of 2,616,131 shares, compared to its average volume of 1,699,897. Autolus Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.50. The firm’s fifty day moving average is $1.59 and its 200 day moving average is $1.55. The firm has a market capitalization of $594.87 million, a price-to-earnings ratio of -2.04 and a beta of 2.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Institutional Trading of Autolus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Marex Group plc bought a new position in shares of Autolus Therapeutics during the second quarter valued at $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the 3rd quarter worth about $46,000. Federation des caisses Desjardins du Quebec acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $62,000. Finally, Invesco Ltd. lifted its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.